🏛️ Verified NIH Record • Updated 2026-06-17
REMASTer: REcurrent Brain Metastases After SRS Trial (NCT05124912)
🟢 Recruiting Observational / Diagnostic 💊 Investigational Drug / Biologic Sponsor: Monteris Medical
🩺 Plain-English Summary (8th-Grade Level)
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (16 items) and avoid the listed exclusions (13 items).
Location: UCLA — Los Angeles, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study:
- Patients with greater than 3 progressing lesions at time of enrollment. To classify as a radiographically progressive, lesion must demonstrate a ≥ 25% increase in size following treatment based on the RANO criteria. Of note, there is no exclusion for total number of metastases. However, only one lesion can be selected to be the targeted lesion and this lesion alone may be ablated during the study procedure.
- Patients with concomitant newly diagnosed intracranial metastases (concurrent with the targetable radiographically progressive lesion), as these will require prioritized and different treatment approaches.
- Prior bevacizumab use within 4 weeks of study initiation
- Patients with additional concurrent malignancies requiring active treatment, except non-melanoma skin cancer, or in-situ cancer of the cervix
- Patients with a serious active infection or other serious underlying medical conditions that would impair the ability of the patient to complete the protocol related QOL questionnaires and cognition assessments
- Inability to tolerate or contraindication to steroid therapy (i.e., dexamethasone)
- Deemed ineligible or unable to tolerate SRS therapy by treating neurosurgeon and/or radiation oncologist
- Patients with any condition that would prohibit them from undergoing a surgical procedure, at the discretion of the treating physician team
- Patients unwilling or unable to give consent for participation
- Patients unable to comply with study requirements
- Patients with diffuse leptomeningeal disease
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (9 Sites)
- UCLA — Los Angeles, California
- University of Chicago — Chicago, Illinois
- University of Maryland — Baltimore, Maryland
- WashU — St Louis, Missouri
- Duke University Hospital — Durham, North Carolina
- Wake Forest Baptist Medical Center — Winston-Salem, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Kettering Health — Kettering, Ohio
- Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.